Grail, Inc. (NASDAQ:GRAL - Get Free Report) shares dropped 11.1% during trading on Wednesday . The stock traded as low as $20.78 and last traded at $21.00. Approximately 660,289 shares traded hands during trading, a decline of 38% from the average daily volume of 1,059,131 shares. The stock had previously closed at $23.62.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on the company. Guggenheim started coverage on Grail in a report on Thursday, October 17th. They issued a "neutral" rating on the stock. Morgan Stanley began coverage on Grail in a research report on Wednesday, November 27th. They set an "equal weight" rating and a $16.00 price objective for the company. Finally, Wolfe Research started coverage on Grail in a research report on Friday, November 15th. They issued a "peer perform" rating on the stock.
Check Out Our Latest Stock Report on Grail
Grail Trading Down 23.4 %
The business has a 50-day moving average of $16.27.
Insider Transactions at Grail
In related news, CFO Aaron Freidin sold 30,452 shares of Grail stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $14.02, for a total transaction of $426,937.04. Following the sale, the chief financial officer now directly owns 268,277 shares in the company, valued at $3,761,243.54. This trade represents a 10.19 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Chun R. Ding purchased 7,629 shares of the firm's stock in a transaction on Tuesday, October 1st. The stock was acquired at an average price of $13.52 per share, with a total value of $103,144.08. Following the completion of the transaction, the insider now owns 3,503,655 shares in the company, valued at approximately $47,369,415.60. This trade represents a 0.22 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 58,829 shares of company stock worth $757,298.
About Grail
(
Get Free Report)
GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.
Featured Articles
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
